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Background

Methods

New Mexico has long experienced challenges associated with opioid use disorder (OUD)
■
■
■

■

In 2017, New Mexico had the seventeenth highest drug overdose death
rate in the United States.1
Between 2013-2015 there was an 82% increase in opioid overdose
related emergency department visits.1
In 2017, of the 332 overdose deaths in New Mexico, the most common
drugs causing overdose deaths were prescription opioids followed by
heroin.2
In 2017, 22% of patients with chronic opioid prescriptions (12,400
patients) were identified to be in need of treatment for OUD3

Medication-Assisted Treatment (MAT), including buprenorphine, is the mainstay
maintenance therapy for OUD. In order to prescribe buprenorphine, providers must
complete an 8 hour DEA-X waiver training.

■

■

■
■
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The number of UNMH GIM attendings who had already completed DEA-X
waiver training were identified. During a GIM monthly meeting, the QI project
was presented and GIM attendings were surveyed via RedCap.
The survey was comprised of 21 questions assessing attitudes toward OUD and
buprenorphine, reservations about prescribing buprenorphine, interest in
obtaining a DEA-X waiver, and schedule availability for future DEA-X waiver
trainings.
Participant attitudes and barriers were analyzed using a five-point Likert scale,
by assigning 1 to strongly agree through 5 to strongly disagree.
Attitudes and common reservations were identified by grouping and summing
the agreed and strongly agreed responses.
Based on provider availability, a list of DEA-X waiver training dates were
provided to the GIM attendings.

Results
■

■

■

13 out of 20 GIM attendings were surveyed. 12 respondents (92%) thought
OUD is a chronic disease. 13 (100%) thought increasing buprenorphine
availability is important. Six (46%) were interested in becoming DEA-X waiver
trained.
The top reservation to completing the training was insufficient time available in
the provider’s current patient schedule (77%), followed by insufficient work
time dedicated to complete the training (54%). Office staff stigma was the least
concerning reservation (23%).
Based on our interventions, 3 attending physicians signed up and completed the
DEA-X waiver training, resulting in a 100% increase in DEA-X waiver trained GIM
attendings at UNMH.

Figure 1: GIM Attending Attitudes

AIM Statement

Conclusion & Next Steps

Given the heavy burden of OUD in New Mexico, our aim was to increase the number of
General Internal Medicine (GIM) attending physicians at the University of New Mexico

Although 100% of GIM attendings surveyed thought increasing the
availability of Buprenorphine was important, only 46% were interested in
becoming DEA-X waiver trained themselves

st

(UNMH) who have completed DEA-X waiver training to 50% by January 1 , 2020
Figure 2: GIM Attending Reservations
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Given the top reservations among GIM attendings, for our next PDSA cycle we
plan to work with clinics to host a DEA-X waiver training on-site and during
normal work hours or during a division faculty meeting to decrease some of the
burden and increase the number of physicians trained.
54% of attendings agreed that having residents who are DEA-X waiver trained
would encourage them to become trained too. We successfully coordinated
with the UNMH IM department to incorporate DEA X-waiver training into the
curriculum for all IM residents. We will continue our efforts to incorporate this
training for future resident cohorts.
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